Etanercept for treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Blood

Volumn 113, Issue 12, 2009, Pages 2868-2869

  Frangoul, Haydar ^a   Koyama, Tatsuki ^b   Domm, Jennifer ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; INFLIXIMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASSISTED VENTILATION; CAUSE OF DEATH; CORTICOSTEROID THERAPY; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC PNEUMONIA SYNDROME; IDIOPATHIC PNEUMONIAN SYNDROME; LETTER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 63849196201     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-177733     Document Type: Letter

References (4)

1. Yanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor: etanercept on the treatment of idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. Blood. 2008;112:3073-3081.
2. Yanik G, Hellerstedt B, Custer J, et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:395-400.
3. Keates-Baleeiro J, Moore P, Koyama T, Manes B, Calder C, Frangoul H. Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant. 2006;38: 285-289.
4. Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood. 2003; 102:2777-2785.